CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04881240
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:45.123199+00:00
Published At: 2025-12-23T00:00:00+00:00
Record Updated At: 2025-12-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia, Refractory", "Pediatric ALL"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-23"
protocolSection.identificationModule.nctId: "NCT04881240"
protocolSection.identificationModule.officialTitle: "A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients \u2264 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.